Clinical trial of XF 73
Latest Information Update: 05 Oct 2021
At a glance
- Drugs Exeporfinium chloride (Primary)
- Indications Skin and soft tissue infections
- Focus Adverse reactions
Most Recent Events
- 05 Oct 2021 New trial record
- 27 Sep 2021 According to a Destiny Pharma media release, The project will be led, managed and funded by CMS. Destiny Pharma will contribute scientific advice as required through a steering committee to the expert dermatology team at CMS.
- 27 Sep 2021 According to a Destiny Pharma media release, the company's China regional partner and investor, China Medical System Holdings Limited (CMS) is establishing a new programme with XF-73 targeting the prevention and treatment of superficial skin infections caused by bacteria.